FacebookTwitterLinkedInContact UsLabrix.com


Laboratory, Endocrine, & Neurotransmitter Symposium

February 15 - 17, 2019

Las Vegas, NV

CMES will be available

Gain additional clinical insight and treatment considerations to evaluate some of the most prevalent and challenging conditions that patients present with, including depression, anxiety, altered mental focus and stamina, sexual dysfunction, sleep disturbances, addictions and dependencies, weight management, and chronic disease. Click the button below to be the first to know when registration for LENS 2019 opens.


Wellness Wednesday

Webinar Series

Topic: Abnormal Menstrual Bleeding with a Focus on Dysfunctional Uterine Bleeding

By: Tori Hudson, ND

November 7, 2018

Join Labrix clinical staff and special guests on the first Wednesday of every month at 9:30 AM and 12:00 PM PST. This free, live webinar series will cover a variety of neuroendocrine topics that will enhance your knowledge, with clinically applicable testing and treatment considerations.



Irvine, CA: October 20, 2018

Stop by the Labrix booth at the NAEM conference in California this weekend, to speak with Labrix East Coast Sales Representative Alicia Waleske.



Nashville, TN: October 25-30, 2018

Labrix will be in Tennessee for the IFM conference later this month. Chat with Labrix National Sales Manager Heather Cadwallader to learn more about testing with Labrix and Doctor's Data.



Portland, OR: October 26-28, 2018

Labrix representatives will be exhibiting at the IWHIM conference in Portland, Oregon later this month. Labrix staff physician Ruth Hobson ND will be presenting "Addressing the Unseen: The Powerful Role of PTSD, Anxiety, Depression and Sexual Dysfunction May Play in Fertility Issues."


Progesterone and Bone Health


Published on 10/17/18

The connection between estrogen and bone health is well established in the medical literature and well-known in the medical community. Estradiol promotes osteoblast activity, the cells in bone that are responsible for the synthesis and mineralization of bone. During periods of lower estradiol levels such as menopause, the osteoblasts cannot produce bone effectively. This partially explains why osteoporosis diagnoses are increasingly common after menopause, and why estrogen replacement is among the FDA-approved treatments for osteoporosis.

Progesterone is a lesser known but equally important hormone in the prevention and treatment of osteoporosis. Bioidentical progesterone therapy has shown promising benefits for bone health in both in vivo and in vitro studies. At a cellular level, progesterone acts on osteoblasts by increasing their differentiation. Estradiol is a necessary part of this process as it stimulates progesterone receptors in osteoblasts. Also important to note is that dosage is important. More is not necessarily better. Physiologic doses of progesterone can increase osteoblast differentiation while supra-physiologic doses suppress this activity.

Progesterone impacts bone health throughout a woman’s entire life. Beginning in the teen years, progesterone levels influence bone density: bone formation increases during the luteal phase of the menstrual cycle when progesterone levels are at their highest. Young women with normal progesterone levels and normal ovulatory cycles have been shown to achieve a higher gain in peak bone mass than their counterparts with lower progesterone levels. Observational studies have linked ovulatory cycles with bone mineral density (BMD) increases, and ovulatory disturbances with BMD decreases.

One of the most powerful influences on ovulation and progesterone levels in young women is the use of combined hormonal contraceptives (CHC), containing supra-physiologic doses of ethinyl estradiol and progestin, the synthetic (non-bioidentical) form of progesterone. CHCs suppress ovarian function which leads to lower progesterone levels leading to a lower gain in peak bone mass. This process can lead to an increased risk of bone-loss-related fractures later in life. Maintaining normal progesterone levels and ovulatory cycles during the teen years can lead to better bone health throughout life.

During perimenopause, women tend to have normal estrogen levels but declining progesterone levels. As a result, bone metabolism changes significantly during this time with increased bone resorption and loss. Women with a lower proportion of ovulatory cycles tend to have more bone loss than those who ovulate more regularly during this time.

Later in life, bioidentical progesterone supplementation can be considered an integral part of the treatment plan for osteoporosis. Among one-hundred patients treated in a clinical setting, progesterone was shown to increase BMD and decrease the chances of fractures in postmenopausal women with osteoporosis. These findings don’t overshadow the fact that estradiol has been more extensively studied in the treatment of osteoporosis, as these two hormones can be combined for a more comprehensive treatment approach. Choosing the right delivery method and formulation are critical as combined topical bioidentical progesterone and estradiol has been shown to create the most significant increase in BMD when compared to non-bioidentical oral combined hormone therapy and controls.

The Comprehensive Hormone Profile can serve as a valuable tool for both assessing your patients’ endogenous hormone production and guiding your treatment plan. Optimizing your patients’ hormone levels can contribute to preventing and treating osteoporosis in your female patients of all ages.



Prior JC. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric (2018); 21(4): 366-374.

Prior JC. How can we protect peak bone mass and future health for adolescent women? -By supporting ovulation and avoiding combined hormonal contraception use. Rev Paul Pediatr (2017); 35(2): 121-124.

von Mach-Szczypiński J, Stanosz S, Kościuszkiewicz J, Safranow K. New aspects of postmenopausal osteoporosis treatment with micronized estradiol and progesterone. Ginekol Pol (2016); 87(11):739-744.

Seifert-Klauss, Schmidmayr M, Hobmaier E, Wimmer T. Progesterone and bone: a closer link than previously realized. Climacteric (2012); 15 (Suppl 1): 26-31.

Schmidmayr M, Magdolen U, Tubel J, Kiechle M, Gurgkart R, Seifert-Klauss V. Progesterone enhances differentiation of primary human osteoblasts in long-term cultures. The influence of concentration and cyclicity of progesterone on proliferation and differentiation of human osteoblasts in vitro. Geburtshilfe Frauenheilk (2008); 68: 722–8.

Lee JR. Is natural progesterone the missing link in osteoporosis prevention and treatment? Medical Hypotheses (1991); 35: 316-318.


The Anti-Anxiety Diet

by Ali Miller, RD, LD, CDE

When addressing a chief complaint of anxiety, don’t forget about the role of progesterone, estrogen’s lesser-known hormone cousin.  Labrix’ tester Ali Miller, RD, LD, CDE explains that when progesterone levels are insufficient, anxiety, racing thoughts, worry and insomnia can take hold.  Progesterone is calming to the nervous system and provides support to the parasympathetic nervous system.  When the sympathetic nervous system is running the show, progesterone levels drop and imbalances pursue. If your patients with anxiety are experiencing irregular cycles, amenorrhea, infertility or are in a transitional period of perimenopause or menopause, consider salivary hormone testing in order to objectively measure progesterone levels.

To find out more about Ali’s comprehensive approach to anxiety, check out her book, The Anti-Anxiety Diet at www.alimillerrd.com/the-anti-anxiety-diet/.  

Click Image for Amazon Link*


Disclaimer: All information given about health conditions, treatment, products, and dosages are for educational purposes only and do not constitute medical advice.